ArticleChemical science2026
Design of permeability-optimized target-binding macrocycles
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrocyclic peptides represent a promising therapeutic modality for challenging targets, such as protein-protein interactions. However, their clinical utility is often limited by inadequate membrane permeability, which restricts both intracellular target access and oral bioavailability. Existing structure-based generative methods for cyclic peptide design prioritize structural validity and binding affinity, yet lack mechanisms to co-optimize membrane permeability. Here we present CycDiff-DPO, a preference-aligned diffusion framework for designing target-specific macrocyclic peptide binders with optimized membrane permeability. By ranking sampled candidates with a Caco-2 permeability predictor and constructing preference pairs, CycDiff-DPO aligns the generative distribution toward permeability-favorable chemical space while preserving target binding competence. We benchmarked CycDiff-DPO across 56 protein targets, finding higher predicted Caco-2 and PAMPA permeability across multiple independent predictors, alongside superior binding energetics and comparable stereochemical quality relative to baseline methods. Case studies on Keap1-Nrf2 and SPSB2-iNOS confirm that top designs recapitulate hot-spot interactions and maintain stable bound poses in molecular dynamics simulations. CycDiff-DPO provides a framework for permeability-enhanced macrocyclic peptide design with broad therapeutic applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.